Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line of Katherine Xu - Credit Suisse.
Katherine Xu - Credit Suisse
Stephen, I was just wondering with regards to the Phase 2/3 study of Ambien versus, or adipiplon versus Ambien CR there’s the four-way cross over, what is the treatment period, length of the treatment.
Stephen R. Davis
I’ll let Ken Sprenger elaborate, but the treatment period, there will be a couple of nights in the sleep lab on drug, and it will average that and that is the same paradigm that we used in the crossover study we did previously.
Kenneth J. Sprenger, M.D., M.B.B.Ch
Two nights for each exposure for each drug that they are exposed to a placebo, and then a washout period of at least five days before the next one.
Stephen R. Davis
And that would be typical of crossover studies of this nature.
Katherine Xu - Credit Suisse
Any conferences that you are going to present at in 2008?
Kenneth J. Sprenger, M.D., M.B.B.Ch
Yes, we have a paper at the APA in May, which in fact, is some of the primate data that Steve had mentioned earlier. And we also have a couple of posters at the APSS in June.
Operator
We have a question from the line of Kim Lee - Pacific Growth Equities.
Kim Lee - Pacific Growth Equities
Quick question on your financial guidance and going forward, where do you expect R&D to fall based on levels from Q4?
Stephen R. Davis
Our R&D total spending for the year will be less than it was for 2007, and we expect that as I mentioned earlier on the call, we’ll be doing more in this year than we did in 2007 in the clinic, but be obviously burning less. We expect R&D expenses for the year for the 12-month period, Kim, to be in the vicinity of $50 million.
Kim Lee - Pacific Growth Equities
And SG&A will be about at the same levels as last year?
Stephen R. Davis
SG&A will be lower than that. And that will probably be in the $8 to $10 million range.
Operator
There are no other questions at this time.
Stephen R. Davis
Let me just sum-up by saying as we’ve discussed, we expect a lot of news for this year. We’ve got a very full portfolio, as we’ve discussed we’ll be very focused on the clinical development portfolio, and producing what I think will be very important data across the entire set of programs that we have. So, thank you very much for dialing-in and we’ll look forward to keeping you posted as we progress throughout the year.
- To read the full transcript on Seeking Alpha, click here »
